Compare Abbott Laboratories (ABT) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs BIO-TECHNE Corp — how do they compare? Abbott Laboratories trades at $109.64 (market cap $187.95B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Abbott Laboratories is far larger — about 16.7× BIO-TECHNE Corp's market cap, and Abbott Laboratories pays the higher dividend (2.32%). Which is the better fit depends on your goals.
| ABT | TECH | |
|---|---|---|
Market Cap | $187.95B | $11.24B |
Sector | Health | Health |
52-Week High | $136.62 | $72.29 |
52-Week Low | $82.57 | $43.31 |
Enterprise Value | $214.96B | $11.32B |
Dividend Yield | 2.32% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $107.80, down slightly by 0.14% today. The stock shows a bullish technical signal with strong moving average support and a consensus analyst price target of $120.70. Recent earnings beat expectations in Q1 and Q2 2026, while revenue grew to $44.33 billion in 2025. The company secured a CE Mark for its Libre Duo glucose-ketone sensor, highlighting innovation in diabetes care.
The outlook remains positive given analyst consensus and recent product approvals, but risks include competitive pressures and macroeconomic volatility. Upside potential exists if earnings momentum continues, though valuation multiples are above industry averages, warranting caution on significant expansion.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
